Cancer drug fails to show better patient survival

03/8/2005 | Reuters

Seattle-based Cell Therapeutics reported a late-stage trial failed to show its experimental lung cancer drug extended patient survival any more than standard chemotherapy. The company said the survival rate for patients with non-small cell lung cancer who received a combination of Xyotax and carboplatin was the same as patients who received paclitaxel in combination with carboplatin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ